The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers

Hydroxylation of R(+)- and S(−)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes

(2012) Hideo Shiohira et al.   PHARMACEUTICAL RESEARCH

Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes

(2011) Hideo Shiohira et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Drug-Drug Interaction Profiles of Proton Pump Inhibitors

(2010) Ryuichi Ogawa et al.   CLINICAL PHARMACOKINETICS

A Randomized Controlled Trial: Efficacy and Safety of Azithromycin, Ofloxacin, Bismuth, and Omeprazole Compared With Amoxicillin, Clarithromycin, Bismuth, and Omeprazole as Second-Line Therapy in Patients WithHelicobacter pyloriInfection

(2010) Mohammad Minakari et al.   HELICOBACTER

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

(2008) Katsuyoshi Sugimoto et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Stereoselective Disposition of Proton??Pump Inhibitors

(2008) Tommy Andersson et al.   CLINICAL DRUG INVESTIGATION

Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy

(2003) Miyuki Kimura et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY